T his study examined the effect of tesaglitazar (GALIDA™), a dual peroxisome proliferatoractivated receptor (PPAR)α/γ agonist, on postprandial metabolism.
Introduction
Emerging evidence suggests that postprandial dyslipidaemia is associated with both atherosclerosis 1-3 and coronary heart disease, 4, 5 and thus is indicative of atherogenic risk. 6 Elevated plasma triglyceride levels are a key feature of the postprandial state in patients with type 2 diabetes mellitus and insulin resistance. 7, 8 Postprandial plasma triglyceride concentrations are dependent on the balance between hepatic and intestinal production of triglyceride-rich lipoproteins and the clearance of remnant particles and very-low-density lipoprotein (VLDL) through the action of lipoprotein lipase (LPL). 6 The increase in plasma concentrations of triglyceride-rich lipoproteins observed in the postprandial state is exaggerated in insulin resistance since the inhibitory effect of insulin on VLDL synthesis is attenuated. 6 Elevated postprandial triglyceride levels are also associated with the depletion of high-density lipoprotein cholesterol (HDL-C) and a predominance of small, dense low-density lipoprotein (LDL) particles -the hallmarks of atherogenic dyslipidaemia. 9 Impaired glucose tolerance (IGT) is associated with impaired secretion of insulin and insulin resistance. 10 In patients with IGT, fasting plasma glucose levels often remain within the normal range generally and the glucose abnormality becomes apparent only in the postprandial phase. Postprandial hyperglycaemia is a risk indicator for microvascular complications and an independent, albeit weak, risk factor for cardiovascular disease, among patients with type 2 diabetes mellitus and in those with pre-diabetes. [11] [12] [13] [14] [15] Therapeutic control of postprandial hyperglycaemia has been associated with a lowering in the incidence of cardiovascular events in patients with impaired glucose tolerance. 16 Therefore, controlling both postprandial lipid handling and glucose tolerance may lower vascular risk. Improvements in postprandial metabolism can be achieved through lifestyle modification and with pharmacological therapies. Tesaglitazar is a dual peroxisome proliferator-activated receptor (PPAR)α/γ agonist that was in development until recently for the treatment of the glucose and lipid abnormalities associated with type 2 diabetes mellitus and insulin resistance. It was evaluated in phase III clinical studies but its clinical development was discontinued in May 2006 because its overall benefit:risk profile did not provide additional benefit to patients compared with other currently available therapy, primarily because of renal effects (elevated serum creatinine levels and a reduced glomerular filtration rate). Earlier clinical trials investigated the efficacy and safety of tesaglitazar in patients with manifestations of insulin resistance (Study in Insulin Resistance, SIR) 17 and type 2 diabetes mellitus (Glucose and Lipid Assessment in Diabetes, GLAD). 18 These were dose-ranging, placebo-controlled trials in which patients received tesaglitazar once daily for 12 weeks. Both studies reported improvements in lipid and glucose metabolism and insulin sensitivity. In the SIR, tesaglitazar 1 mg significantly reduced the primary outcome measure of fasting triglycerides by 37%, lowered fasting plasma free fatty acids (FFA) by 40% and increased HDL-C by 16%. 17 Tesaglitazar 1 mg also produced significant reductions in fasting insulin (-35%) and plasma glucose concentration (-0.47 mmol/L). 17 This paper describes the findings for a pre-specified objective of SIR, which was examination of the effect of tesaglitazar on postprandial lipid and glucose metabolism in a subpopulation of patients.
Methods
The study was performed in accordance with the Declaration of Helsinki, in line with Good Clinical Practice and regulatory requirements. The protocol and any amendments were approved by local ethics committees.
The SIR (SH-SBT-0001) was a randomised, double-blind, placebo-controlled, parallel-group dose-finding study to investigate the effects of tesaglitazar (GALIDA™, AstraZeneca) on glucose and lipid abnormalities in patients with manifestations of insulin resistance (specifically, hypertriglyceridaemia and abdominal obesity). The detailed study design has been reported elsewhere. 17 A pre-specified secondary objective of the SIR was to assess whether tesaglitazar also improved postprandial lipid and glucose metabolism in a subgroup of patients.
Patients
Male outpatients over 30 years of age and female postmenopausal outpatients were recruited for the SIR trial in 42 centres in seven countries, including Denmark, Germany, Hungary, Norway, Poland, Sweden and the UK. It was planned that 180 of 360 patients planned for recruitment into the SIR trial would receive an oral glucose tolerance test (OGTT) and standardised mixed meal (SMM) to assess postprandial parameters. Subpopulations involved in the postprandial analysis were limited to one centre in Denmark, one in Germany, seven in Norway and six in Sweden.
Patients were required to provide signed informed consent for the trial and were enrolled at a screening visit 7-9 weeks before randomisation. Inclusion criteria included fasting serum triglycerides (TG) of 1.7-7.0 mmol/L (150-620 mg/dL) that varied by no more than 40% during three visits preceding randomisation, and that remained within the specified range at the randomisation visit. Patients were also required to have a waist:hip ratio of > 0.90 (men) and > 0.85 (women).
Exclusion criteria for the study included fasting serum total cholesterol (TC) > 8.0 mmol/L (> 309 mg/dL); fasting plasma glucose (FPG) > 7.0 mmol/L (> 126 mg/dL); systolic blood pressure (SBP) > 170 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg; body mass index (BMI) > 40 kg/m 2 ; previous major systemic disorder or major disease; concomitant use of oral antidiabetic medication within 12 weeks prior to enrolment; concomitant use of statins, fibrates, nicotinic acid or omega-3 fatty acids within eight weeks prior to enrolment; lipid-lowering therapy within two weeks of enrolment; alcohol or drug abuse; and participation in another tesaglitazar trial within the preceding 12 months.
Treatment
Patients were given standardised advice about diet and lifestyle throughout the trial, including advice on smoking, alcohol consumption and physical activity. After the initial screening, patients received one placebo tablet once daily during a six-week single-blind, run-in period. Patients were then randomised to one of five treatment arms: 0.10, 0.25, 0.5 or 1 mg tesaglitazar, or placebo, to be taken orally once daily in the morning for 12 weeks.
Assessments and data analysis
A subgroup of patients randomised into the SIR received a lipid-rich SMM 30 minutes before tablet intake at baseline and on the last day of the 12-week treatment period. Subjects were instructed to refrain from all food for 12 hours and alcohol for 24 hours before each visit, and they were also asked to refrain from tobacco or nicotine use in the morning before each visit, in order to reduce the confounding effects of these factors. The SMM was prepared according to the method of Karpe. 19 It consisted of pasta, boiled chicken breast, green peas and mayonnaise, and was served with a liquid containing up to 17 g of carbohydrates. The energy content of the SMM was 1,000 kcal for an individual of less than 85 kg body weight and 1,200 kcal for a person with a body weight of 85 kg or more. Fat, carbohydrate and protein contributed 60%, 27% and 13% of the total energy content, respectively. The nutrient composition of the 1,000 kcal and 1,200 kcal meals was 68 and 82 g of fat, 66 and 79 g of carbohydrate, and 33 and 37 g of protein, respectively. The meal was to be consumed within 15 minutes and venous blood samples were taken via an indwelling plastic cannula immediately before and 60, 120, 180, 240, 300 and 360 minutes after consumption. Blood samples were measured for serum triglycerides, plasma glucose, plasma insulin, serum glycerol and plasma non-esterified fatty acids (NEFAs). All variables were measured using standard To convert triglyceride to mg/dL, divide by 0.0112; to convert insulin to mU/L, divide by 6.0
Key: BMI = body mass index, ITT = intention-to-treat; OGTT = oral glucose tolerance test; SD = standard deviation; SMM = standardised mixed meal Key: AUC = area under curve; CI = confidence intervals; NEFA = non-esterified fatty acids; SD = standard deviation; SMM = standardised mixed meal laboratory procedures, with Quest Diagnostics (Heston, UK) acting as the central laboratory.
The postprandial area under the concentration-time curve (AUC) 0-6 h after the SMM was determined for each variable. If the last postprandial value was assessed more than six hours after the administration of the SMM, the area was cut at six hours. The AUCs were not calculated for patients who did not have a fasting value before receiving the SMM, or if the last postprandial value was assessed less than five hours after the SMM had been served, or if there were fewer than four postprandial assessments of the laboratory variable.
The incremental postprandial AUC was calculated in the same way as the postprandial AUC, except that the fasting value was deducted from all laboratory variables. Therefore, the incremental AUC could be negative.
The OGTT was performed before tablet intake, three days before the randomisation visit (baseline) and three days before the end of the 12-week treatment period. Venous blood samples to analyse plasma glucose were collected immediately before and 60 and 120 minutes after intake of a solution containing 75 g glucose. The solution was consumed within five minutes and patients were prohibited from doing any physical activity during the two-hour test period.
Changes in efficacy variables were analysed using a fixedeffect analysis of covariance (ANCOVA), with treatment and country as factors and the baseline value as covariate. Placebo-corrected changes from baseline are presented as estimates and two-sided 95% confidence intervals (CIs). The CIs were corrected with Dunnet's method for multiple comparison within the subgroups.
The AUC and incremental AUC of glucose after the OGTT were determined in the same way as for postprandial AUC. Descriptive statistics were presented for incremental AUCs.
Data were calculated and presented based on the intention-to-treat (ITT) principle. The ITT population included all randomised subjects who took at least one dose of the double-blind study medication.
Details of the sample size calculation have been published previously. 17 Enrolment in the SIR planned to include 700 patients, and the OGTT and SMM were to be conducted in 50% of patients. Based on the previously defined conditions, with approximately 25 patients per treatment group (50 patients for placebo), it was possible to detect a mean difference of 20% between tesaglitazar-treated patients and the placebo group, with respect to change in postprandial triglycerides with 90% power.
Results
A total of 397 patients were randomised into the SIR study, and 222 received both an SMM and an OGTT. Of these, 195 patients were included in the ITT analysis. There were no significant differences in the baseline characteristics between patients studied (table 1). The patient population was insulin-resistant as indicated by elevated fasting plasma insulin levels. Furthermore, baseline characteristics were not notably different from those reported for the entire SIR cohort. 17 All the patients included in the SIR trial were white.
Postprandial measurements
Standardised mixed meal Significant reductions in postprandial AUC for all assessed variables were observed following treatment with tesaglitazar. Tesaglitazar 0.25, 0.5 and 1 mg reduced postprandial AUC for triglycerides by 20% (p=0.003), 30% (p<0.0001) and 41% (p<0.0001), respectively (table 2). In addition, treatment with tesaglitazar 1 mg for 12 weeks reduced triglyceride levels at all time points following the SMM (figure 1) . Similarly, dose-dependent reductions in the postprandial AUC for NEFA and glycerol were seen following tesaglitazar treatment for 12 weeks. Levels of NEFA were reduced by 17% at 0.5 mg doses (p=0.002) and by 29% at a 1 mg dose (p<0.0001). Changes in glycerol were also significant for tesaglitazar 0.5 and 1 mg, with reductions of 19% (p=0.01) and 34% (p<0.0001), respectively (table 2) . Reductions in the AUC for postprandial insulin and glucose were significant for tesaglitazar 1 mg. Reductions in insulin AUC of 31% (p<0.0001) and glucose AUC of 2.4 h x mmol/L (p=0.0009) were observed at this dose (table 2). The difference in plasma levels for all assessed variables was apparent at each time point throughout the six-hour postprandial period but diminished towards the end, when comparing placebo and the 1 mg dose of tesaglitazar after 12 weeks' treatment (data not shown). Dose-dependent improvements in incremental AUC from baseline were demonstrated for triglycerides, glycerol and insulin after the SMM (table 3) . There was no clear reduction in incremental AUC for NEFA and no change in incremental AUC for glucose (table 3) .
Oral glucose tolerance test
Tesaglitazar significantly improved glucose tolerance and increased the proportion of patients with normal glucose tolerance. An improvement in two-hour glucose levels during a standard OGTT following tesaglitazar treatment for 12 weeks was observed, with a statistically significant effect for tesaglitazar 1 mg (table 4) . At baseline, 72-87% of patients had OGTT results within the normal range of < 7.8 mmol/L. After 12 weeks of treatment, the percentage of patients within the normal range increased for all doses of tesaglitazar (table 5) . Among patients who received tesaglitazar 1 mg, all had normal glucose tolerance at study end. In contrast, the percentage of patients in the placebo group who had normal glucose tolerance decreased from 82% at baseline to 75% at the end of the study.
Discussion
This study clearly demonstrated that in hypertriglyceridaemic, GALLANT STUDY abdominally obese, non-diabetic patients, treatment with tesaglitazar once daily for 12 weeks significantly improved lipid and glucose levels for up to six hours following an SMM. The reduction in postprandial triglycerides was significant for the 0.25, 0.5 and 1 mg doses of tesaglitazar. As individuals with typical Western diets can be in an almost constant postprandial state, the durability of the changes in postprandial lipid and glucose metabolism with tesaglitazar may be clinically relevant. 20 Many of the processes involved in lipid metabolism are insulin-sensitive; insulin resistance gives rise to elevated triglyceride levels. 7, 8, 21 A reduction in insulin resistance, demonstrated in the overall population in the SIR, 17 may have partially restored the effectiveness of insulin in inhibiting the secretion of triglyceride-rich particles in the fasting stage and during the postprandial phase.
Tesaglitazar is a dual PPARα/γ agonist; modulation of the PPARs is likely to underlie its postprandial effects. Modulation of PPARγ also upregulates lipoprotein lipase (LPL) in adipocytes 22 and decreases postprandial NEFA concentrations. [23] [24] [25] Both these actions could further contribute to the improved postprandial triglyceride response by increasing the rate of lipolysis of triglycerides and by decreasing the substrate for triglyceride production in the liver, respectively. LPL activity was not measured in the current study but tesaglitazar did decrease postprandial exposure to NEFA, although it did not clearly reduce incremental AUC for NEFA.
Fibrates (which are PPARα agonists) reduce postprandial triglyceride levels by 30-50%, 26 and also reduce fasting triglyceride levels, by stimulation of LPL and by inhibition of apoC-III expression. In addition, pioglitazone (which has some PPARα agonist properties) can lower levels of triglycerides in the fasting state. 25 Therefore, a proportion of the lowering of fasting triglyceride levels and, consequently, of the smaller postprandial elevations observed with tesaglitazar, is likely to be attributable to its PPARα agonist properties. The lowering of plasma glucose, as well as the reductions in fasting 17 and postprandial insulin levels, by tesaglitazar could also theoretically contribute to the lowering of postprandial triglycerides. 27, 28 Glucose tolerance was significantly improved for tesaglitazar 0.5-and 1 mg-treated patients, and tesaglitazar treatment increased the number of patients with IGT who converted to results within the normal glucose range after 12 weeks of treatment. The improvement in OGTT results was particularly apparent with tesaglitazar 1 mg, such that all patients taking this tesaglitazar dose had normal glucose tests at 12 weeks. Moreover, although the absolute postprandial glucose levels may differ following an SMM and an OGTT, the patterns of improvements in glucose values following both tests were similar.
This study measured the AUC of postprandial triglycerides to evaluate postprandial effects. Incremental AUC has been suggested as an alternative measure because it only reflects the post-challenge increase, whereas the AUC is strongly influenced by fasting triglyceride levels. 29 The pattern of postprandial improvement with tesaglitazar was still apparent when incremental AUC was calculated. The other variables also showed similar changes whether the effects were determined by AUC or incremental AUC, except for the incremental AUC for NEFA and glucose, which were not reduced.
A limitation of the study is that all women who participated in the study were postmenopausal. Menopause has been shown to increase postprandial lipaemia, probably due to loss of up-regulation of hepatic LDL receptors by oestrogen. 30 Consequently, the results seen with tesaglitazar cannot be extrapolated to women of all ages. A further consideration is that all the subjects in the current study were white. As there are racial differences in postprandial responses, with postprandial lipid triglyceride levels being lower in blacks than whites, 31, 32 the findings of this study may not be directly applicable to other racial groups.
In summary, treatment with tesaglitazar once daily for 12 weeks resulted in significant improvements in the postprandial AUC of triglycerides, glucose, insulin, glycerol and NEFA in insulin-resistant, non-diabetic patients. Current evidence suggests a link between postprandial elevations in triglycerides and the development of atherosclerosis, 1-3 with the evidence being less strong for postprandial increases in glucose. [11] [12] [13] Therapeutic interventions to improve postprandial lipaemia and glucose excursion may potentially affect the risk of cardiovascular disease. The development of tesaglitazar, and also that of muraglitazar (another dual PPARα/γ agonist, which was associated with a greater incidence of death, major cardiovascular events and congestive heart failure), has been halted. Nevertheless, in the future, if the safety issues could be addressed, dual PPARα/γ agonists might be beneficial in improving glycaemic control and reducing cardiovascular risk in patients with type 2 diabetes mellitus.
